Reduced-Dose Apixaban and Rivaroxaban Versus Low-Molecular-Weight Heparin in Patients With Hematologic Malignancies

This study is comparing two approaches to preventing dangerous blood clots in people with blood cancers (like multiple myeloma, lymphoma, or leukemia) who are undergoing cancer treatment. It compares lower-dose blood thinning pills (apixaban or rivaroxaban) to standard injectable blood thinners (low-molecular-weight heparin). **You may be eligible if...** - You have an active blood cancer and are starting or currently receiving cancer treatment - Your doctor has assessed you as being at intermediate or high risk of blood clots (Khorana score of 2 or more) - You are already taking or being considered for one of the blood thinners included in the study **You may NOT be eligible if...** - You have had a major bleeding episode recently - You have kidney problems severe enough to affect blood thinner dosing - You are pregnant or breastfeeding - You require anticoagulation for a different reason (like an existing clot or atrial fibrillation) Talk to your doctor to see if this trial is right for you.